Clinical Trial Detail

NCT ID NCT02811809
Title Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer
Recruitment Withdrawn
Gender male
Phase Phase II
Variant Requirements No
Sponsors Robert J Amato
Indications

prostate adenocarcinoma

Therapies

Leuprolide

Apalutamide + Leuprolide

Age Groups: adult senior

No variant requirements are available.